二甲基硅油/氢氧化铝/氢氧化镁(Dimethicone/Aluminum hydroxide/magnesium dihydroxide) - 药物靶点：Proton pump_在研适应症：十二指肠溃疡，胃肠胀气，胃溃疡_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Gelusil、Mintox

靶点

Proton pump

作用机制

质子泵抑制剂

治疗领域

消化系统疾病其他疾病

在研适应症

十二指肠溃疡胃肠胀气胃溃疡

非在研适应症-

原研机构-

在研机构-

非在研机构-

最高研发阶段批准上市

首次获批日期-

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式AlH3MgO4Si

InChIKeyAUNJGAJRTBKKGS-UHFFFAOYSA-K

CAS号8077-28-9

关联

3

项与二甲基硅油/氢氧化铝/氢氧化镁相关的临床试验

NCT01982201 / Completed临床1期

A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects

This study will assess the potential effects of calcium carbonate and aluminum/magnesium hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of lesinurad in healthy, adult male subjects.

开始日期2013-11-01

申办/合作机构

Ardea Biosciences, Inc.

NCT01622673 / Completed临床1期

A Study to Evaluate the Effect of Metal Cation-Containing Antacids on Raltegravir Pharmacokinetics in HIV-Infected Subjects on a Stable Raltegravir-Containing Regimen

This study will evaluate: (1) the effect of co-administration of single doses of calcium carbonate antacid and magnesium/aluminum hydroxide antacid on the steady-state plasma pharmacokinetic profile of raltegravir in human immunodeficiency virus (HIV)-infected participants; and (2) the effect of staggered dosing of a single dose of a magnesium/aluminum hydroxide antacid 2 hours before and 2 hours after administration of raltegravir on the steady-state plasma pharmacokinetic profile of raltegravir in the same participants.
The study will determine whether (1) the C12hrs of steady-state raltegravir after co-administration of single doses of calcium carbonate antacid is decreased to a clinically meaningful degree compared with C12hrs after administration of raltegravir alone; and whether (2) the C12hrs of steady-state raltegravir after co-administration of a single dose of magnesium/aluminum hydroxide antacid is decreased to a clinically meaningful degree compared with the C12hrs after administration of raltegravir alone.

开始日期2012-06-01

申办/合作机构

Merck Sharp & Dohme Corp.

NCT00703534 / Completed临床2期

Validation of Patient-reported Outcomes Measures for the Assessment of GERD Symptoms and Their Subsequent Impact on Patients With Partial Response to Proton Pump Inhibitor (PPI) Treatment in a Two Part Multi-center Phase IIa Study Including a Four Week Randomised, Double-blind, Placebo-controlled, Parallel-group Treatment Period

This research study is being done to gather information about how to do further clinical studies using AZD3355 as an add-on treatment to proton pump inhibitors (PPI).

开始日期2008-05-01

申办/合作机构

AstraZeneca PLC

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的临床结果

登录后查看更多信息

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的转化医学

登录后查看更多信息

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的专利（医药）

登录后查看更多信息

23

项与二甲基硅油/氢氧化铝/氢氧化镁相关的文献（医药）

2023-10-01·Chemistry & Biodiversity

Quantification of Phytochemicals and Metal Ions as well as the Determination of Volatile Compounds, Antioxidant, Antimicrobial and Antacid Activities of the Mimosa pudica L. Leaf: Exploration of Neglected and Under‐Utilized Part

Article

作者: Rawat, Hemant ; Prasad, Shyam Baboo ; Ramamurthy, Praveen C ; Singh, Simranjeet ; Jha, Sudhanshu Kumar ; Mishra, Sujeet K ; Webster, Thomas J ; Gandhi, Ms Yashika ; Kumar, Vijay ; Mrkute, Akshada ; Singh, Arjun ; Singh, Ravindra ; Grewal, Jyotika ; Gupta, Akhil ; Charde, Vaibhav ; Tandon, Smriti ; Singh, Gagandeep ; Srikanth, Narayan ; Narasimhaji, Ch Venkata ; Acharya, Rabinarayan ; Soni, Hemant

AbstractMimosa pudica L. (MP) is well‐known plant in traditional medicinal system, especially in India. Unfortunately, leaves of MP are less explored. To determine the food and nutritional value of the neglected part of Mimosa pudica L. (MP), that is MP leaves, phytochemicals and metal ions of MP were quantified by newly developed HPLC and ICPOES‐based methods. The content of phytochemicals observed using HPLC analysis for chlorogenic acid, catechin, and epicatechin was 141.823 (±8.171), 666.621 (±11.432), and 293.175 (±12.743) μg/g, respectively. Using GC/MS/MS analysis, fatty acid like oleic acid were identified. In ICP‐OES analysis, a significant content of Na, K, Ca, Cu, Fe, Mg, Mn, and Zn was observed. The observed TPC and TFC for MP leaf extracts was 44.327 (±1.041) mg GAE/ g of wt. and 214.217 (±4.372) mg QCE/ g of wt., respectively. The DPPH assay depicted a strong antioxidant activity of MP leaf extracts with IC50 values of 0.796 (±0.081) mg/mL and a TEAC value of 0.0356 (±0.0003). A significant antacid activity (666 mg MP+400 mg CaCO3 >400 mg CaCO3 ≫666 mg Gelusil) of MP leaves was noticed. The methanolic extract of MP leaves demonstrated anti‐microbial activity against Staphylococcus aureus (15±2mm), Pseudomonas aeruginosa (12±2mm) and Escherichia coli (10±2mm). In silico studies confirmed the in vitro results obtained for antioxidant, antiacid, and anti‐microbial activities. In addition, in silico studies revealed the anti‐cancerous and anti‐inflammatory potential of the MP leaves. In summary, this study demonstrated the medicinal significance of MP leaves and the conversion of agro‐waste or the under‐utilized part of MP into pharmaceutical potent materials. Consequently, the present study highlighted that MP leaves alone have medicinal importance with good nutritional utility and possess large promise in the pharma industry along with improving bio‐valorization and the environment.

2011-07-01·Pakistan journal of pharmaceutical sciences

Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.

Article

作者: Nair, Dhanya Kondayil ; Bharathi, Natarajan ; Ravi, Thengungal Kochupapy ; Muruganathan, Gandhimathi

Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. Fluoroquinolones are known to have interactions with drugs that are active in gastro intestinal tract. Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. The interaction was studied at neutral, acidic and basic conditions both at room temperature and 37°C. The effect of dissolution medium simulating various body environments with response to pH has been examined in order to elucidate the interactions. The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. It was seen that interaction of these fluoroquinolones was more at 37°C than at room temperature. Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. The study ensures the interaction of fluoroquinolones with selected class of drugs. In order to achieve the effective therapeutic effect appropriate time intervals between administrations of drugs is essential.

2003-01-01·Alimentary Pharmacology & Therapeutics1区 · 医学

Pantoprazole maintenance therapy prevents relapse of erosive oesophagitis

1区 · 医学

Article

作者: Wilkofsky, Steven ; Behar, Jose ; Kovacs, Thomas ; Kogut, David ; Rodgers, John ; Snape, William ; Schlesinger, Paul ; Wagonfeld, James ; Feldman, Saul ; Blitstein, Mark ; Giannella, Ralph A. ; Riff, Dennis ; Metz, David C. ; Bochenek, W. J. ; Hee, Vernon ; Karras, Peter J. ; Safdi, Alan ; Achord, James L. ; Orchard, John ; Rai, Anirudh ; Redinger, Richard ; Kornfield, Robert ; Meister, Thomas ; Wu, Wallace ; Avner, Dennis ; Aaronson, Richard ; Schwartz, Howard I. ; Pambianco, Daniel ; Harford, William V. ; Miner, Philip ; Rosenberg, Stanley ; Jones, James V. ; Winston, Barry D. ; Wruble, Lawrence

SummaryObjectives : To compare the safety and efficacy of pantoprazole with ranitidine for the maintenance of endoscopically documented healed (grade 0 or 1) erosive oesophagitis.Methods : Patients (371) were randomly assigned to receive pantoprazole 10, 20 or 40 mg or ranitidine 150 mg. Endoscopies were performed after 1, 3, 6 and 12 months or when symptoms suggesting relapse (grade = 2) developed. Gastric biopsies were obtained at baseline and on at least one postbaseline visit. Symptom‐free days and Gelusil use were assessed.Results : Pantoprazole was significantly (P < 0.001) more effective in maintaining erosive oesophagitis healing. After 12 months, 33%, 40%, 68% and 82% of patients remained healed for the ranitidine and pantoprazole 10, 20 and 40 mg groups, respectively. Daytime and night‐time heartburn were eliminated in > 90% of days for the pantoprazole 40 mg group. Gelusil use was significantly lower with pantoprazole 20 and 40 mg than with ranitidine (P < 0.02) during the first 9 months.Conclusions : Twelve months of maintenance therapy with pantoprazole (10–40 mg once daily) was superior to ranitidine (150 mg twice daily) in maintaining erosive oesophagitis healing. Pantoprazole 40 mg provided the most consistent efficacy and was well tolerated.

100 项与二甲基硅油/氢氧化铝/氢氧化镁相关的药物交易

登录后查看更多信息

研发状态

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
十二指肠溃疡	中国	-	-
胃肠胀气	中国	-	-
胃溃疡	中国	-	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00703534 (C27, CTgov)	临床2期	胃食管反流 \| 胃灼热	478	Gelusil®+AZD3355 (AZD3355)	夢糧襯製鬱鹹鹹艱製顧(壓鏇鏇製膚襯廠願齋餘) = 廠簾廠網夢鏇製網鏇鏇壓築鑰鑰壓鏇鏇獵築醖 (糧齋遞鏇遞簾衊構觸醖, 鬱憲繭膚觸獵鹹壓願蓋 ~ 網糧窪觸壓淵廠糧繭艱) 更多	-	2011-06-20
				Placebo+Gelusil® (Placebo)	夢糧襯製鬱鹹鹹艱製顧(壓鏇鏇製膚襯廠願齋餘) = 廠廠顧蓋製積醖範觸糧壓築鑰鑰壓鏇鏇獵築醖 (糧齋遞鏇遞簾衊構觸醖, 積窪蓋繭顧構壓繭衊餘 ~ 齋觸觸衊鬱繭夢夢夢鬱) 更多